Nureca swings to profit, bets ₹100 cr on Punjab plant
The medical devices maker reported ₹2.97 crore in net profit for FY26 on 28% revenue growth. The ₹100 crore capex is 37% of its market capitalisation.
— 1 earlier story on Nureca Ltd. →What's new
- Nureca posted a ₹2.97 crore net profit for FY26, up from a ₹6.68 crore net loss the prior year.
- Board approved up to ₹100 crore in additional capex for a Punjab facility making medical devices and hygiene products.
- CFO Naresh Gupta will step down June 26, replaced by internal promotion Chander Kant from June 27.
Why this matters
The ₹100 crore commitment is significant relative to Nureca's size. It signals management is doubling down on in-house manufacturing, pivoting from whatever model produced a ₹6.68 crore loss just a year ago. The internal CFO promotion keeps financial leadership aligned with that bet, but the scale of spend relative to market cap raises execution risk.
What we're watching
- Whether FY26's profit holds up as the capex cycle begins and depreciation hits the P&L.
- The funding plan for the ₹100 crore outlay — debt, internal accruals, or another raise.
- Chander Kant's first quarterly results and any shift in financial strategy.
The full read
Nureca is putting ₹100 crore into a Punjab plant to make its own medical devices and hygiene products. For a company with a ₹267 crore market cap and a ₹2.97 crore net profit, that's a major bet on vertical integration. The move comes as the company just finished a turnaround, swinging from a ₹6.68 crore net loss to profit on 28% revenue growth to ₹147.2 crore. The CFO, Naresh Gupta, is leaving. His replacement, Chander Kant, is an internal promotion. The timing is notable: Nureca is about to spend roughly 37% of its market value on capacity expansion just as it proves it can make money. The open question is whether the profit stays in place once depreciation and financing costs from this buildout hit the books.
Questions answered
- How big is the approved capex relative to Nureca's size?
- The ₹100 crore incremental capex is about 37% of the company's ₹267 crore market capitalisation. It dwarfs the existing property, plant, and equipment base described in the rationale.
- What is Nureca's current financial trajectory?
- Nureca swung from a net loss of ₹6.68 crore in FY25 to a net profit of ₹2.97 crore in FY26, supported by 28% revenue growth to ₹147.2 crore.
- Why is the CFO changing right now?
- Naresh Gupta is stepping down to pursue other opportunities. The company is promoting internal finance manager Chander Kant to ensure continuity as it embarks on the major capital expansion.
- What will the Punjab facility produce?
- The expanded capacity will focus on manufacturing medical devices and hygiene products, shifting more production in-house under the new investment plan.
Story so far
All notes on NURECA →- 29 May 2026 · 8:41 PM IST Nureca swings to profit, bets ₹100 cr on Punjab plant
- 1d ago Nureca's new filing is paperwork. The only news is a new director.